Podcasts about CNS

Midlife is a time for rebirth… a time to come into who you truly are.  In today's episode, I'm sitting down with the brilliant Dr. Deanna Minich to dive into how this stage of life can bring you to the best version of yourself after years of balancing roles, expectations, and responsibilities.  Dr. Minich shares why midlife is the perfect time to rediscover your voice, clarify your needs, and define your non-negotiables so you can live the next chapter on your own terms.  We're reframing menopause not as an ending, but as the beginning of a powerful second half of life filled with purpose and authenticity.  Ready to reclaim your energy and step into midlife with clarity and confidence?  Tune in here!  Deanna Minich, PhD, MS, CNS, IFMCP Deanna Minich is a nutrition scientist, international lecturer, educator, and author with over 25 years of experience in academia and in the food and dietary supplement industries. She's the Chief Science Officer at Symphony Natural Health, and has written seven books and over 50 scientific publications. Her work aims to help others live well by using therapeutic lifestyle changes that impact their physical, emotional, mental, and spiritual health. IN THIS EPISODE Uncommon signs that you're entering  perimenopause  The importance of musculoskeletal strength in midlife What's really going on with female hormones in perimenopause  Setting boundaries in midlife in your relationships and career Balancing lifestyle changes and hormone replacement therapy for optimal results  How to navigate stress and manage your nervous system Finding your authentic self in perimenopause and beyond How to connect with Dr. Deanna for more midlife expertise  QUOTES “I think it's a really powerful system and I think the best thing for women, no matter if you're going through perimenopause, you're just about to enter, or even if you're post, it's really connecting into that wisdom within that we have as the endocrine system.” “There's no way I could ever do women's health on my own. I want to be connected to a collaborative, to a team, to other people in the space where we rise together and we really get the message out. So that's what I've been doing.” “Here's the message for women: we all need a way to bring ourselves into better coherence, better emotional, mental status, like where we feel in the zone.” RESOURCES MENTIONED Use code ENERGIZED and get 10% off on your Troscription Order http://troscriptions.com/ENERGIZED Dr. Deanna's Website Dr. Deanna on Instagram Dr. Deanna on Facebook Symphony Natural Health Website RELATED EPISODES  724: Age Like A Girl: Why Midlife Women Stop Shrinking and Start Leading with Dr. Mindy Pelz  721: No, It's Not All in Your Head: The Medical Truth About Perimenopause with Dr. Jila Senemar 720: Why No One Talks About Loneliness in Midlife—And Why It's Not Just You  574: The Connection between Trauma, the Immune System, and Autoimmune Disease: Lab Testing and Solutions with Dr. Sara Szal Gottfried

Pete Moore, Longtime Athletic Trainer & Motivational Speaker, joins Dan Tortora (DT) fresh off of going to support Upstate NY Native & CNS Northstars Alum, Arkansas RB, & 2026 NFL Draft Prospect RB Mike Washington, Jr., speaking on Mike Washington from his many years knowing & working with him, experiencing what Mike did at the 2026 NFL Combine, & helping kids in general, including CNS, UConn, & WNBA Superstar Breanna Stewart, with a focus foremost on God & in wanting to see people be the best they can be, regardless of outside noise... Stay close to "WakeUpCall" on Facebook, X, & Instagram! Listen LIVE to "Wake Up Call with Dan Tortora" MON through FRI, 9-11amET on wakeupcalldt.podbean.com & on the homepage of WakeUpCallDT.com from ANY Device inside the Great Lakes Honda City Studios (7140 Henry Clay Blvd, Liverpool, NY)! You can also Watch LIVE MON through FRI, 9-11amET on youtube.com/wakeupcalldt, facebook.com/wakeupcalldt, & facebook.com/LiveNowDT. This special is Proudly Presented by: Carvel DeWitt Great Lakes Honda City Meier's Creek Brewing Company The Wildcat Sports Pub Ma & Pa's Kettle Corn & Popcorn Factory Willow Rock Brewing Company Brian's Landing K-9 Kampground Dog Boarding Game Point Sports Complex Binghamton University Pizza Man Pub Chick-fil-A DeWitt K-9 Kamp Dog Daycare Avicolli's Restaurant Mother's Cupboard Chick-fil-A Cicero

Listen Online: About this episode: In this powerful episode, the First Lady of Nutrition sits down with Juliette Harch — multiple sclerosis survivor and wife of renowned hyperbaric oxygen therapy (HBOT) pioneer Dr. Paul Harch — to explore one of the most under-discussed tools in neurological recovery: oxygen under pressure. Juliette shares how her eyesight was failing, her energy collapsing, and her body quietly signaling that something was very wrong. She opens up about the possible triggers behind her diagnosis — including heavy diet soda consumption and mercury dental fillings — and how targeted hyperbaric therapy helped restore her vitality. Ann Louise and Juliette also discuss today's growing wave of concussions and traumatic brain injuries in both children and adults, and why untreated head injuries can quietly alter behavior, cognition, and long-term brain health. Juliette explains why dose and precision matter profoundly in HBOT — and how the right protocol can mean the difference between incremental change and meaningful neurological recovery.  Ann Louise adds insight from her own injury experience, deepening the discussion even further. If you or someone you love is navigating MS, brain injury, or cognitive decline, this conversation may shift how you think about healing.The post Can Oxygen Therapy Help REVERSE MS? first appeared on Ann Louise Gittleman, PhD, CNS.

Nutritional Support for Brain Health: Lifestyle, Curcumin, Magnesium, and Key Nootropics: Nutrition educator/formulator Neil Levin from Protocol for Life Balance details nutritional support for brain health amid skepticism about “brain-boosting” supplements, citing a preprint randomized controlled trial using a multifaceted lifestyle plan (diet, exercise, sleep) plus targeted supplementation that reportedly improved and even reversed symptoms in people with mild cognitive impairment. They contrast lifestyle strategies with costly, side-effect-prone injectable “plaque-buster” Alzheimer's drugs and notes debate about whether amyloid is a root cause or byproduct. The conversation highlights inflammation and oxidation as major aging-related brain threats and reviews supplements including a brain-targeted curcumin (discussing bioavailability, delivery methods, blood–brain barrier crossing, and claims of lowering beta-amyloid protein), magnesium L-threonate for CNS delivery, phosphatidylserine and acetylcholine support (including huperzine), ginkgo and gotu kola, glutamine/GABA pathways, creatine, omega-3s (DHA/EPA and algae sources), B vitamins, acetyl-L-carnitine, alpha-lipoic acid, and cocoa flavanols, plus concerns about supplement industry enforcement.

In this episode of The Nurse Practitioner Podcast, Julia Rogers, DNP, APRN, CNS, FNP-BC, FAANP, FAAN and Patti Ludwig-Beymer, PhD, RN, CTN-A, NEA-BC, CPPS, FTNSS, FAAN discuss mentoring.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.

Dr. Maya Graham interviews Dr. Lauren Schaff on her manuscript entitled "Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL)," published in Neuro-Oncology in January 2026.

In this episode, Greg and I covered everything from LASIK stories and gym culture to CGMs and deloads, but the real theme was intentional living. We both did an unplanned digital detox over the weekend — no social media, no constant email checking, no reacting to every notification. And nothing broke. Sales still came in. Emails could wait. What we gained instead was presence — with family, with training, with real life.Phones have become the adult pacifier. Scrolling doesn't solve anxiety, boredom, or stress — it just numbs it. Time is the only non-renewable resource we have. If you're physically present but mentally tethered to your device, you're absent. So I'm doubling down on boundaries: batching emails, no reactive mornings, fewer distractions, more depth. When you remove noise, you amplify what actually matters.We also talked training — a strategic deload using machines to reduce CNS fatigue while keeping intensity high — and my current CGM experiment. Heavy training spikes glucose slightly. OMAD with high fat? Flat line. Data reinforces the philosophy: adequate fat stabilizes the response. And no, I didn't promote high fat to sell Keto Bricks — I built Keto Brick because I needed it first. Which is fitting, because March marks eight years since launch. Eight years of refining, leveling up, and doing the work.Key Takeaways:Digital detox creates clarity and presence.Most “urgent” communication isn't actually urgent.Boundaries protect your time and energy.Strategic deloads can increase long-term performance.High-fat OMAD keeps glucose remarkably stable (for me).Standards matter in natural bodybuilding — pro cards should be earned.Talk is cheap. Execution wins.Next episode we'll be reporting back post–Tough Mudder — cold, muddy, and better for it.Greg Mahler is also a lifetime natural bodybuilder, and can be followed on Instagramhttps://www.instagram.com/ketogreg80/Register For My FREE Masterclass: https://www.ketobodybuilding.com/registration-2Get Keto Brick: https://www.ketobrick.com/Subscribe to the podcast: https://open.spotify.com/show/42cjJssghqD01bdWBxRYEg?si=1XYKmPXmR4eKw2O9gGCEuQ

Episode 214: Valley Fever Complications. Dr. Arreaza:
Welcome back to the podcast. I'm Dr. Arreaza, and today we're talking about a topic that's very relevant here in the Central Valley but often not well known in the rest of the country, it is called ValleyFever, or coccidioidomycosis. For more info about the Valley Fever diagnosis and initial treatment, please go to our previous podcast on the subject! Episode 143, recorded by wonderful Dr. Lovedip Kooner.  To help us walk through this, I'm joined by Jordan, a medical student. Jordan, welcome back and Dr. Schlaerth, please introduce yourself.  Jordan:
Thanks, Dr. Arreaza. This is such an important topic, especially in endemic areas like where we live, the Central Valley of California, and Arizona. The public may think of Valley Fever as a mild pneumonia that just goes away eventually. But that's not always the case. Some patients develop serious, life-altering complications, and a small but important number develop disseminated disease. Dr. Arreaza:
Exactly. So today, we're going to break this down systematically: pulmonary complications, dissemination to other organs, CNS disease, musculoskeletal involvement, systemic symptoms, and then we'll touch on treatment principles and why follow-up matters so much. Dr. Schlaerth: Valley Fever can be missed in areas where it is not as common as in the Valley. 1989, earthquake in LA.Pneumonias that is not responding to treatment can be pulmonary cocci. Dr. Arreaza:
Before we dive into specific complications, let's zoom out. What percentage of patients get a complicated disease? Jordan:
So, most infections are self-limited, but about 5–10% of patients develop chronic or progressive pulmonary disease, and 1% develop extrapulmonary disseminated disease. That sounds small, but given how common Valley Fever is in endemic areas, that's still a lot of people. Dr. Arreaza:
And the complications can be devastating, and they are not always in primary infection. Dr. Schlaerth: Dissemination can be silent. We don't know exactly why dissemination happens; some ethnicities are more susceptible or other groups. Dr. Arreaza:
Let's start where Valley Fever usually begins: the lungs. What are the major pulmonary complications clinicians should know about? Jordan:
The most common long-term complications are chronic pulmonary sequelae. These include: cavitary disease, pulmonary nodules, bronchiectasis, pulmonary fibrosis, and pleural complications like effusions, empyema, or pneumothorax. Dr. Arreaza:
Cavitary disease comes up a lot. What does that look like clinically? Jordan:
Cavities form in about 5–15% of cases. Many are asymptomatic, but symptomatic cavities can cause fever, fatigue, cough, sputum production, dyspnea, and hemoptysis. The tricky part is that symptoms often wax and wane, and even with treatment, current antifungals don't eradicate the organism from chronic cavities. Dr. Arreaza:
That's very unfortunate, and sometimes those cavities remain and patients might not know that they have them, and those cavitary lesions may rupture. Jordan:
Yes, rupture can lead to pyopneumothorax, which is a surgical emergency requiring prompt intervention. Dr. Kooner: Hello everyone, this is Dr. Kooner, and today I want to talk about one of my favorite topics: coccidioidal cavitary disease—because nothing says “fun lung pathology” like a hole in the lung that refuses to leave. Coccidioidal cavitary disease is a chronic pulmonary manifestation of infection. Many times, it's found incidentally on imaging. Sometimes patients are being evaluated for respiratory symptoms, sometimes for systemic complaints, and sometimes for something completely unrelated—like when a chest X-ray was ordered for a pre-op clearance and suddenly… surprise cavity. Pulmonary cavities develop in about 5-10% of patients with Valley Fever. Most of the time, they appear as thin-walled residual lesions. They can be solitary or multiple, and they can range from a few centimeters to much larger. And while textbooks love to show the “classic look,” in real life they can be a little more… creative. These cavities can persist for years. Some patients feel completely fine and never know they have one. Others develop chronic symptoms or complications like rupture into the pleural space, secondary infection, or bleeding, which is when everyone suddenly becomes very interested in that cavity. Here's an important teaching point: about 20% of patients with cavitary disease also have disseminated infection, most commonly involving bone. This challenges the old-school teaching that cavitary lung disease and dissemination rarely happen together.  One major risk factor for cavitary disease—and for more severe or complicated infection overall—is diabetes mellitus. So how do patients usually present? Symptoms often overlap with classic Valley Fever symptoms. The most common presenting symptoms for cavitary disease that usually trigger evaluation are cough, hemoptysis, fever, and shortness of breath. Diagnosis and monitoring rely heavily on chest imaging. Plain chest X-rays are usually enough for stable disease. CT scans are typically saved for when you're worried about complications. Serologic testing is also key, especially complement fixation titers. In general, higher titers correlate with more severe disease and higher relapse risk. Management depends on symptoms and host factors.If the patient is asymptomatic and immunocompetent, they often don't need antifungal therapy. These patients can usually be followed with periodic clinical and imaging monitoring watch closely and don't panic. Symptomatic patients are typically treated with oral triazoles, most commonly fluconazole or itraconazole. Treatment is long—usually at least 6 to 12 months, and often longer—because symptoms love to come back once therapy stops. These medications are usually suppressive rather than curative, although newer data suggests triazoles may help with cavity closure in some patients. Relapses happen in about 25 to 33% of immunocompetent patients, and even more often in immunocompromised patients or transplant recipients. Many of these patients end up needing long-term or even indefinite therapy. Not ideal—but still better than uncontrolled disease. Surgery still has a role, but it's more selective now. It's usually reserved for complications like life-threatening hemoptysis or rupture into the pleural space. Early ruptures might be managed with chest tube drainage. More complicated or delayed cases may need decortication or lung resection. So, the big picture: symptomatic coccidioidal cavitary disease can be a chronic management challenge. It requires individualized treatment decisions, prolonged therapy for many patients, and long-term follow-up with imaging and serologic monitoring to catch relapses early and prevent complications. And if there's one takeaway, it's this: if you find a stable cavity in someone known to have Valley Fever, sometimes the best move is careful monitoring—not chasing it with endless tests that make everyone nervous, including the patient. Thanks for listening—and remember, sometimes the lung keeps souvenirs from infections… and sometimes those souvenirs stick around for years. Now, let's continue with the discussion about pulmonary nodules. This is Dr. Kooner, signing off.    

Autism, Functional Medicine, and Personalized Interventions: A Conversation with Theresa Lyons, PhD, a Yale-trained scientist and medical strategist who became an autism expert after her daughter's diagnosis and now runs AWEtism.net. Lyons describes dissatisfaction with conventional guidance that offers limited drugs for irritability and primarily ABA (Applied Behavioral Analysis), which is insurance-covered, often recommended at 40 hours/week, uses extrinsic rewards, and may help some skill-learning but has controversies and limitations for social development; she contrasts newer approaches such as RDI (Relationship Development Intervention) and PRT (Pivotal Response), which aim to build intrinsic motivation but are typically not covered by insurance. The discussion covers autism heterogeneity, changes in diagnostic categories (e.g., Asperger's folded into autism), and research including a Boston Children's Hospital study reporting 37% of children in a cohort lost their autism diagnosis over time (diagnosis based on observation). Lyons addresses debates about rising autism prevalence, noting multiple potential contributors and rejecting single-cause explanations, while citing risk-factor examples such as family autoimmune history and air pollution exposure. She outlines a functional medicine “why” approach using constipation as an example (root causes vs. symptomatic treatment), and emphasizes basic, low-risk steps such as evaluating diet, inflammation, hydration/electrolytes, and blood work for nutrients. Specific topics include gluten-free approaches (mechanisms involving gut permeability, immune burden, and CNS effects), dairy/inflammation, vitamin D deficiency and monitoring, melatonin as a well-studied short-term aid in autism (considered safe for a couple of years in studies) while still seeking underlying causes, and omega-3 fatty acids for focus and inflammation. Lyons explains leucovorin (folinic acid, prescription vitamin B9) as a targeted approach for children with folate receptor antibodies (reported in ~70% of autistic children), discusses the value and cost (~$300) of specialized testing from one U.S. lab, and notes reports of major speech and behavior improvements in responders, with dosing nuances. The episode also reviews evidence and cautions around the microbiome, including fecal microbiota transplant (FDA-approved for C. difficile; discussed as having an ~80% response rate in autism-related studies when gut issues are a key driver, but with major donor/compatibility considerations) and probiotics (some small trials and high costs). Other themes include “clean eating,” organic foods and toxin-load considerations tied to genetic detoxification vulnerabilities, discussion of acetaminophen/Tylenol in pregnancy in the context of glutathione pathways and personalized risk, and using genetics to guide interventions. Lyons warns that analysis of top autism TikTok videos found ~70% were inaccurate or overdramatized, recommending social media only for ideas, not decision-making. She also highlights parent stress, citing emerging research on increased PTSD risk among autism parents, and emphasizes support and community. Lyons advises parents to understand their child's specific health drivers and match them to appropriately specialized clinicians, noting her curated doctor listings in The Lyons Report.

PsychopharmaPearls is NEI's focused podcast series highlighting the clinical insights that can sharpen your prescribing decisions. In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression. They unpack the differences that truly matter in practice—from patient selection and monitoring to access, cost, and common missteps. Tune in for practical pearls you can immediately apply to select the right treatment for the right patient.  Lisa Harding, MD is a board-certified psychiatrist and nationally recognized depression specialist with deep expertise in interventional psychiatry. She has performed more than 4,000 procedures, including electroconvulsive therapy (ECT), intravenous ketamine, intranasal esketamine, and transcranial magnetic stimulation (TMS). Dr. Harding is known for her thoughtful approach to complex, treatment-resistant depression, integrating advanced somatic therapies, psychopharmacology, and psychotherapy. She serves as an Assistant Clinical Professor of Psychiatry at Yale University in New Haven, Connecticut.  Andrew J. Cutler, MD is a leading psychiatrist, psychopharmacology expert, and clinical researcher with decades of experience in CNS drug development. As Chief Medical Officer of Neuroscience Education Institute and EMA Wellness, he brings frontline clinical insight together with deep knowledge of the evidence base. Dr. Cutler is widely recognized for translating research into practical guidance for everyday practice and serves as a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Sanacora G et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080  McIntyre RS et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251    Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring    Never miss an episode!

This is the full story of the first-ever Burpee Broad Jump Marathon — 42.195 km completed in burpees across 8 days (197 hrs). For athletes, adventurers, and creators who want to turn an absurd idea into global impact. Watch how Mann, a 22‑year‑old from New Delhi planned, suffered, and inspired a movement.What You'll Learn In This Video-What a burpee broad-jump marathon actually is and how the record was set-The training mindset and low-mileage-to-goal strategy used for extreme endurance-Logistics: stadium, team, sponsorships, medical challenges, and execution-The mental/physiological dark points (electrolytes, sleep, CNS fatigue) and recovery-How the event created cultural impact and opportunities afterwardVIDEO CHAPTERS (TIMESTAMP FORMAT)00:00 – Hook: intro & record announcement00:33 – What the burpee marathon actually is (rules & mechanics)02:00 – Scale of the feat: laps, hours, logistics03:20 – Background: childhood, football in Europe, privilege & purpose06:30 – Why this felt unconventional for someone from India08:10 – Training progression: how he built to multi-hour sessions10:00 – Organising the stadium, permits, team and funding headaches12:20 – Starting day one: weather, chaos, and the early community response15:00 – Mid-event realities: fatigue, medical issues, and vivid dreams18:40 – Darkest moments & pushing through (sodium/urine pain)21:10 – Unexpected outcomes: media, love from strangers, cultural impact23:05 – Aftermath: recovery, lost drive, and lessons learned24:40 – Future plans: business, whales, adventure with purpose26:20 – Closing message & final advice: “Plant your tree — focus on process”#BurpeeMarathon #WorldRecord #ManVsBurpee #EnduranceChallenge #UltraEndurance #IndiaAthlete #AdventureWithPurpose #197Hours #BurpeeWorldRecord #MentalEndurance #StadiumChallenge #CNSRecovery #YoungAthlete #UnconventionalPathburpee marathon, burpee world record, man vs burpee, burpee broad jump marathon, 197 hours burpees, endurance challenge, ultramarathon burpees, Indian athlete story, adventure with purpose, training for extreme events, CNS fatigue recovery, low-mileage training strategy, stadium world record, 22 year old record, mental toughness

Listen Online: About this episode: What begins as a conversation about MSG quickly expands into a much larger discussion. The First Lady of Nutrition welcomes back board-certified neurosurgeon Dr. Russell Blaylock to explore excitotoxins — compounds such as glutamate that overstimulate brain cells and often appear on labels under disguised names. He explains how these additives may influence addiction, neurological health, and why they are far more common in the U.S. food supply than in many European countries. The interview also covers neurodegenerative disease, the role of glutamate in cancer growth, and ways to calm excess glutamate activity. Ann Louise and Dr. Blaylock also discuss key nutrients, including high-dose benfotiamine and other B vitamins, and why many neurological conditions like Parkinson’s may be linked to thiamine deficiency. The conversation then broadens to immune function and COVID-related concerns, including neurological effects and post-illness immune changes, along with nutrients and flavonoids involved in regulating the p-53 gene. What starts with food additives ultimately becomes a wider look at how modern exposures may be shaping brain health today.The post The Forgotten Toxicity of MSG and the New Breed of Poisons first appeared on Ann Louise Gittleman, PhD, CNS.

In this episode, we speak with George Mothema, CEO of the Board of Airline Representatives of South Africa (BARSA), to review the state of South African aviation in 2026 and preview the upcoming BARSA conference in KwaZulu-Natal. George highlights positive market developments including shareholding changes at Safair, Qatar's 25% stake in Airlink, and SAA adding new routes as it rebuilds. Key challenges discussed include ATNS's past neglect of instrument and flight procedure redesigns that led to suspended procedures and losses for airlines serving secondary airports, aging CNS equipment requiring manual workarounds, delayed airport maintenance by ACSA with noted improvements at OR Tambo, and border management bottlenecks such as long passport-control queues and delays implementing e-gates due to slow biometric systems and aging platforms.  Find out more: https://barsa.co.za/  00:00 Welcome to AviaDev Insight Africa + Introducing BARSA CEO George Mothema  01:17 South Africa Aviation 2026: The Good News (market shakeups, new investors, SAA routes) 04:21 The Bad News: ATNS flight procedure suspensions & air traffic systems upgrades 06:23 Airport maintenance & border control bottlenecks 08:27 Policy & safety snapshot: civil aviation policy balance 11:39 Regional recovery & why BARSA is heading to KwaZulu-Natal (Durban)  15:43 Conference theme reveal: "Destination Africa" and what it means 16:07 Program deep dive 22:34 Who should attend BARSA 2026 30:48 Wrap-up.

We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

What happens when a 20 year mental health veteran has her own existential crisis then undergoes her own psychedelic therapy? In Inna Zelikman's case, it completely transformed how she practices medicine.Inna Zelikman, RN, MS, ANP, PMH-NP, is the Director of Integrative Mental Health at Recovery Without Walls and a MAPS certified MDMA practitioner. Five years ago, her own psychedelic healing journey changed everything about how she sees and treats patients. Now she's challenging the cookie cutter protocols that dominate our field in favor of what she calls an "organic" approach to treatment.In this conversation, Inna shares her comprehensive patient assessment strategies, the medication categories that secretly block healing (even though they're not contraindications), and why some patients have profound psychedelic experiences but can still struggle.From consulting with psilocybin centers in Oregon to treating ketamine addiction, Inna offers a nuanced perspective on the complexities of psychedelic medicine and why proper preparation, support, and integration actually matter for lasting results.What You'll Learn:

Clients hitting walls, losing focus, and quitting on the most meaningful reps too soon? Is it the client's fault or the trainer's, without even realizing it? Paradox Strength President Janaya Skye returns to the podcast to talk about something that many trainers don't realize: if you ignore your central nervous system, you're leaving a lot on the table. We dive into how your CNS can affect your workouts and client sessions, what happens – and what to do – when your clients start tuning out instructions, why that happens, and some specific, real-life situations and how to approach them. Make sure that you get those last, greatest reps in to really get the most out of your sessions — tune in to this one! ━━━━━━━━━━━━ Get a FREE course to grow your strength training business here ━━━━━━━━━━━━ Get NEW Precision-Engineered MedX Machines here ━━━━━━━━━━━━ For the complete show notes, links, and resources, click here

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and rare-disease drug development. Michelle traces her two-decade career across Bristol Myers Squibb, AstraZeneca, and Novartis—and the moment everything changed when her child was diagnosed with a rare disease. That experience led her to Alltrna and its pioneering engineered tRNA platform, designed to correct nonsense mutations across hundreds—potentially thousands—of genetic disorders with a single therapeutic approach. Together, Alok and Michelle explore how tRNAs work, why “stop-codon disease” could redefine rare-disease classification, and how basket trials borrowed from oncology may accelerate development. They dive into delivery strategy, portfolio expansion into CNS and muscle disorders, regulatory innovation, and how AI is reshaping molecular design—offering a rare look at what it takes to build a first-in-class modality from the ground up. Biography: Michelle is a seasoned pharmaceutical executive with more than 20 years in the industry spanning commercial and research & development (R&D) responsibilities. Prior to Alltrna, Michelle served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology, where she was responsible for delivering the disease area strategies across multiple tumors and led business development efforts resulting in a doubling of long-term portfolio value for the franchise. Previous to Novartis, Michelle was a senior leader at AstraZeneca and as Global Franchise Head in Hematology, she was critical in launching multiple indications worldwide for CALQUENCE®. Prior to this, Michelle was Head of US Oncology, where she led the business through dramatic growth in both team and revenue through eight-plus product launches. Previous to AstraZeneca, Michelle was with Bristol-Myers Squibb for 10 years in various positions of increasing responsibility including roles in sales, marketing, and market access in the US and UK, and above market in Europe (based in France) and global almost exclusively in oncology. Michelle started her professional career in R&D, working hands-on with patients at the Oncology Clinical Trials Unit at Harvard Medical School before moving into industry in clinical operations. Outside of her corporate responsibilities, Michelle is a wife and mother to three children and is a member of the rare disease community. She is currently serving a Board appointment for the non-profit organization Rare Disease Renegades, a purpose that fuels her passions both personally and professionally.

CDMX despliega más de 300 puntos de vacuna contra sarampión  L2 del Metro tendrá cierres y horario reducido  Hamas cuestiona alto el fuego en GazaMás información en nuestro podcast

Mind Pump Fit Tip: How to Lean Bulk for Lean Gains (Build Muscle, Not Body Fat). (2:38) Easy-to-digest vegan protein shakes. (22:15) Speaking identity. (24:04) Getting too much attention? (30:37) Father first. (32:37) Laser focused on ketones. (37:06) The latest GLP-1 propaganda and the dangers. (40:28) Fun Facts with Justin: Rat Utopia Experiment. (46:57) How extreme intelligence is more correlated to mental illness. (52:30) Being stuck in the past, and pick-up spots for the middle-aged crowd. (1:00:00) #Quah question #1 – How do you know if you're getting actual muscle gain or CNS adaptation? Been lifting for 10+ years. (1:10:53) #Quah question #2 – You've mentioned the bi-weekly method for strength training and cardio for best results. If you were to juggle between two MAPS programs with this method, which two would you bounce between for someone who just genuinely enjoys the benefits of both? (1:13:28) #Quah question #3 – What are some exercises I can do as someone with scoliosis? I want to get back into strength training. (1:17:07) #Quah question #4 – What is a good age to introduce weight training for kids? I have 10- and 7-year-old girls who do recreational sports. (1:18:46) Related Links/Products Mentioned Use code MINDPUMP for an exclusive offer for Mind Pump listeners of 15% OFF! New customers only. "If you're trying to feel a little more put together, or you just want some easy wins in your day, this combo is such a good place to start." Visit: https://huel.com/MINDPUMP  30% OFF your subscription order PLUS receive a free gift with your second shipment—fun surprises like a free 6-pack, Ketone-IQ merch, and more! Or find Ketone-IQ at Target stores nationwide. Visit: https://ketone.com/MINDPUMP February Promotion: Feb 1 - Feb 14th - The Couple's Bundle (Aesthetic, HIIT, Muscle Mommy, No BS 6-Pack Abs), $498 value, only $197!  Visit: https://www.mpvalentine.com  Mind Pump Store Mind Pump #2160: Macro Counting Master Class Mind Pump #2690: The NEW DIET Everyone Is Using For Fat Loss Fig and Eagle Model ex-wife who revealed NFL husband Matt Kalil's manhood size cites 'free speech' in bid to toss lawsuit Kelly Stafford Posts Security Cam Video of Husband Matthew Getting Home at 2:20 AM After NFC Title Loss 'Ozempic Vulva': How GLP-1 Drugs May Lead to Vaginal Changes This Old Experiment With Mice Led to Bleak Predictions for Humanity's Future 7 Surprising Correlations Between Intelligence and Mental Health Visit Fatty15 for an exclusive offer for Mind Pump listeners! ** You can get an additional 15% off their 90-day subscription Starter Kit with code MINDPUMP. Fatty15 is on a mission to optimize your C15 levels to help support your long-term health and wellness - especially as you age. Mind Pump # 2547: Stop Trying to Get Your Kids in Shape! Do This Instead! Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Scott Donnell (@imscottdonnell) Instagram LAUREN FITZ, M.D. (@drlaurenfitz) Instagram Dr. William Seeds (@williamseedsmd) Instagram Dr. Tyna Moore (@drtyna) Instagram   Corinne Schmiedhauser (@mindpumpcorinne) Instagram  

Listen Online: About this episode: In this thought-provoking conversation, Ann Louise Gittleman sits down with neurologist Dr. Thomas Guttuso, Jr., author of The Promise of Lithium, to explore the emerging role of carefully dosed lithium in neurodegenerative disease. Why is Parkinson's now the fastest-growing neurological disease? Dr. Guttuso explains what's driving the surge, how Parkinson's differs from Parkinsonism, and why men are diagnosed more often than women. He also introduces what he calls the brain's “Bermuda Triangle” — a vulnerable region tied to progressive neuron loss — and shares insight into a promising blood marker, neurofilament light (NFL), that may help track early damage. From there, the conversation turns to why dose and form are everything when it comes to lithium — and how the small amounts he uses clinically differ dramatically from the psychiatric doses most people associate with the mineral. He also addresses timing, prevention, L-Dopa, and whether early support could change the trajectory of these conditions. If you're concerned about Alzheimer's, Parkinson's, stroke, MS, or simply protecting long-term brain health, this interview offers a grounded and science-driven perspective on a mineral that may hold broader implications than many realize.  Check out Dr. Guttoso’s book at https://amzn.to/3YUgv4p and the form of lithium he recommends at https://amzn.to/4k7xDxE. The post The Promise of Lithium for Alzheimer's, Parkinson's and MS first appeared on Ann Louise Gittleman, PhD, CNS.

We review diagnosing and managing bacterial meningitis in the ED. Hosts: Sarah Fetterolf, MD Avir Mitra, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Meningitis_2_0.mp3 Download Leave a Comment Tags: CNS Infections, Infectious Diseases, Neurology Show Notes Core EM Modular CME Course Maximize your commute with the new Core EM Modular CME Course, featuring the most essential content distilled from our top-rated podcast episodes. This course offers 12 audio-based modules packed with pearls! Information and link below.  Course Highlights: Credit: 12.5 AMA PRA Category 1 Credits™ Curriculum: Comprehensive coverage of Core Emergency Medicine,  with 12 modules spanning from Critical Care to Pediatrics. Cost: Free for NYU Learners $250 for Non-NYU Learners Click Here to Register and Begin Module 1 Patient Presentation & Workup Patient: 36-year-old male, currently shelter-domiciled, presenting with 3 weeks of generalized weakness, fevers, weight loss, and headaches. Vitals (Initial): BP 147/98, HR 150s, Temp 100.2°F, RR 18, O2 99% RA. Clinical Evolution: Initial assessment noted cachexia and a large ventral hernia. Following initial workup, the patient became acutely altered (A&O x0) and febrile to 102.9°F. Physical Exam Findings: Brudzinski Sign: Positive (knees flexed upward upon passive neck flexion). Kernig Sign: Discussed as highly specific (resistance/pain during knee extension with hip flexed at 90°). Meningeal Triad: Fever, nuchal rigidity, and AMS (present in 40% of cases; 95% of patients have at least two of the four cardinal symptoms including headache). Imaging: Chest X-ray: Scattered opacities (pneumonia) and a small pneumothorax. CT Abdomen/Pelvis: Confirmed asplenia (secondary to 2011 GSW/exploratory laparotomy). Head CT: Ventricle enlargement concerning for obstructive hydrocephalus and diffuse sulcal effacement. CSF Analysis & Microbiology Bacterial Meningitis Opening Pressure: Elevated (Normal is 1000–2000/mm3 WBC); dominated by neutrophils (>80% PMN). Glucose: Low (

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

As awareness of perimenopause- and menopause-related health concerns grows, Neda Gioia, OD, CNS, IFMCP, FOWNS says it is time for the eye care industry to recognize how profoundly hormonal shifts can affect vision and ocular comfort.Dr. Gioia said women experience hormonal transitions that differ significantly from men, yet health care systems do not consistently account for those biological differences. “Men and women are biologically different. We know this,” she says. “The discussion is why are we not actually navigating this difference with our health care system?”

Podcast Miniseries: Cultivating a Culture – Growing a Healthy Neurosurgical Workplace Ep. 3: Leadership at a Scale Guest: Elad Levy Hosts: Brian Gantwerker & Chris Newman In this episode, we sit down with former CNS president and current Chair of the University of Buffalo Department of Neurosurgery Dr. Elad Levy for a wide ranging discussion on leading the CNS. Dr. Levy shares his insights on leadership transitions, setting an agenda, balancing the various opinions in the room, and the lessons learned from his experiences.

To celebrate 101 episodes, I sit with Leonard H. Calabrese, DO, to discuss his unique career in Rheumatology, spanning immunology, HIV, MECFS, IRES, CNS vasculitis and more. We also discuss how medical history shaped our careers.  ·        Intro 0:12 ·        Welcome Leonard H. Calabrese, DO 3:11 ·        A quick friendship begins over medical history 4:14 ·        How Healio Rheuminations began and where the show is now 5:38 ·        How Dr. Calabrese got interested in medical history 7:11 ·        Serotherapy 10:52 ·        Why patients get certain diseases 12:33 ·        Dr. Calabrese's career trajectory 14:43 ·        One day in 1981… 17:52 ·        A few things happened in the 90's 20:20 ·        Tell us about CNS vasculitis 21:53 ·        Don't be afraid to reinvent yourself 24:30 ·        Checkpoint inhibitors 25:09 ·        How do you keep up? 26:43 ·        Placebo science 28:25 ·        Do you think we'll ever be able to answer where diseases come from? 29:33 ·        Thank you, Dr. Calabrese 31:01 ·        Thanks for listening 31:26 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc.,  has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the precise delivery of radiation. Marc explains, "Since we last talked and we discussed primarily the use of radiotherapeutics for the treatment of glioblastoma. We've expanded that pretty significantly into a disease called leptomeningeal metastasis. And I think we may have touched on that briefly, at least conceptually, a few years ago. But now it's really real. We've just completed a phase one trial, and we're expanding that with the goal of getting the drug approved, perhaps sooner than with glioblastoma, by focusing on leptomeningeal cancer, for which there's nothing approved. And maybe it would be a good idea to back up and explain a little bit about what that is, because there's an epidemic of it that's not commonly understood."   "So the central nervous system is a protected organ in the body. Now, I mean the brain and the spinal cord. And it's that way for a reason to keep bad things out. Things like infections, tumors, or certain chemical toxins. And that includes drugs. Only about 2% of all drugs get into the central nervous system, which is a problem from a therapeutic perspective. But there's an epidemic in terms of metastases to the brain and spinal cord. Let's call those the CNS collectively. And that's because many common tumors like breast cancer, lung cancer, gastrointestinal cancers, and melanoma are better controlled locally with drugs that don't have to worry about getting into the central nervous system. They just need to get into those specific organs and tissues and then exert control over the tumor where it occurred."    $PSTV #LM #CNS #Cancer #LeptomeningealMetastases #CNSide #BrainCancer #Oncology #Radiotherapeutics #MedicalInnovation #CancerResearch #Biotechnology #PatientCare #ClinicalTrials #HealthcareInnovation #CancerTreatment #Neuroscience #MedTech plustherapeutics.com Download the transcript here

Dr. Marc Hedrick, President and CEO of Plus Therapeutics Inc.,  has expanded their focus from glioblastoma to leptomeningeal metastasis, a central nervous system cancer that is a growing challenge due to increased survival rates from primary cancers. Their highly sensitive, advanced diagnostic test, CNSide, can detect cancer cells in cerebrospinal fluid, addressing the shortcomings of imaging and outdated standard-of-care practices. Using AI and advanced data analytics, their lead drug candidate is uniquely suited for treating CNS cancers because its safety at high doses enables the precise delivery of radiation. Marc explains, "Since we last talked and we discussed primarily the use of radiotherapeutics for the treatment of glioblastoma. We've expanded that pretty significantly into a disease called leptomeningeal metastasis. And I think we may have touched on that briefly, at least conceptually, a few years ago. But now it's really real. We've just completed a phase one trial, and we're expanding that with the goal of getting the drug approved, perhaps sooner than with glioblastoma, by focusing on leptomeningeal cancer, for which there's nothing approved. And maybe it would be a good idea to back up and explain a little bit about what that is, because there's an epidemic of it that's not commonly understood."   "So the central nervous system is a protected organ in the body. Now, I mean the brain and the spinal cord. And it's that way for a reason to keep bad things out. Things like infections, tumors, or certain chemical toxins. And that includes drugs. Only about 2% of all drugs get into the central nervous system, which is a problem from a therapeutic perspective. But there's an epidemic in terms of metastases to the brain and spinal cord. Let's call those the CNS collectively. And that's because many common tumors like breast cancer, lung cancer, gastrointestinal cancers, and melanoma are better controlled locally with drugs that don't have to worry about getting into the central nervous system. They just need to get into those specific organs and tissues and then exert control over the tumor where it occurred."    $PSTV #LM #CNS #Cancer #LeptomeningealMetastases #CNSide #BrainCancer #Oncology #Radiotherapeutics #MedicalInnovation #CancerResearch #Biotechnology #PatientCare #ClinicalTrials #HealthcareInnovation #CancerTreatment #Neuroscience #MedTech plustherapeutics.com Listen to the podcast here

New rules in China will accelerate the country's cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commercialized. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the new framework and why it will create a powerful incentive for deploying new gene and cell therapies.Executive Editor Selina Koch discusses which milestones she is watching in neurology in the year ahead, from psychedelics to Alzheimer's disease. Finally, Senior Biopharma Analyst Danielle Golovin discusses a pair of stories from BioCentury's Emerging Company Profile series: one focused on Yale spinout Bexorg Inc., which is rethinking CNS drug discovery with a whole-human-brain model, and another on Elkedonia S.A.S., a French start-up aiming at ELK1 to reboot neuroplasticity in depression.View full story: https://www.biocentury.com/article/65818900:00 - Introduction03:14 - Speeding China's Innovation10:36 - Neuro Catalysts22:01 - NewcosTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Listen Online: About this episode: What if one of the biggest reasons we age faster, feel weaker, and lose resilience has nothing to do with hormones or calories — but with minerals? In this rare and deeply personal interview, Ann Louise Gittleman sits down with James Templeton, founder of UNI KEY Health and one of the longest-living Stage 4 melanoma survivors in the world, to reveal why minerals may be the missing link to cellular strength, energy, and longevity. James shares why, after decades of studying nutrition and formulating supplements, he became convinced that minerals are more important than almost anything else we put into our bodies. He explains why modern soil depletion has left most people unknowingly deficient, how mineral loss weakens our cells like a drained battery, and why he went on a global search for the purest mineral source on Earth — ultimately leading to the creation of Mineral-Key, a liquid blend of more than 72 ancient trace minerals from a prehistoric mineral bed millions of years old. Along the way, James opens up about his own cancer journey, what he's learned from interviewing top cancer experts and survivors through the Templeton Wellness Foundation, and the rare trace minerals most people have never heard of — yet desperately need. If you've ever wondered how to help your body stay younger, stronger, and more resilient at the cellular level, this is a conversation you won't want to miss. You can find Mineral-Key at https://unikeyhealth.com/products/mineral-keyThe post A Rare Conversation with One of the Longest-Living Stage 4 Cancer Survivors — And the Mineral Secret That Changed Everything first appeared on Ann Louise Gittleman, PhD, CNS.

In this episode, we're joined by Brady Bielewicz, an advanced practice clinician serving in a blended Acute Care NP and CNS role. Dr. Brady Bielewicz is a trauma ICU advanced practice nurse and Assistant Professor at the University of Pittsburgh School of Nursing. With nearly 15 years of hands-on critical care experience as both an Acute Care Nurse Practitioner and Clinical Nurse Specialist, he brings a real-world perspective that resonates with bedside nurses and APRNs alike. His work centers on trauma education, developing confident advanced practice nurses, and shaping certification exams that truly reflect clinical practice Brady brings a unique perspective on trauma care, interdisciplinary collaboration, and the critical nursing assessments and interventions that truly impact patient outcomes. This episode is called "Be the Change When Seconds Matter: The Power of Nursing in Trauma Care." Brady can be contacted on LinkedIn @BradyBielewicz BCEN & Friends Podcast is presented by the Board of Certification for Emergency Nursing. Scan the QR Code to sign up for Learn Updates: We invite you to visit us online at bcen.org for additional information about emergency nursing certification, education, and much more. Episode introduction created using elevenlabs.io

A large U.S. cohort study found that children who were late for routine 2- or 4-month immunizations were six to seven times more likely to miss MMR vaccination entirely by age two, highlighting early delays as a strong predictor of future vaccine refusal amid rising measles cases. A long-term study of more than 27,000 women showed that very high lipoprotein(a) levels were associated with substantially increased cardiovascular risk over 30 years, supporting targeted one-time screening. Finally, Medicare data revealed that one in four older adults with dementia received CNS-active medications, often without clear indications, underscoring opportunities to reduce inappropriate prescribing.

Program notes:0:38 Childhood vaccinations nationally1:30 Across 45 states and DC2:34 Level of vaccine protection3:34 Professional societies stepping in3:51 Skilled nursing facilities 4:51 Estimated operating capacity5:51 Backups into hospitals6:51 Staffing not returned to pre-pandemic levels7:35 Prescribing patterns of CNS active meds in older adults8:36 Several classes of medication examined9:36 Last line medications9:50 Mifepristone regulation historically10:50 Consistent findings on safety11:50 FDA looking at REMS12:50 End

In this podcast, experts Sara A. Hurvitz, MD, FACP, Michelle Melisko, MD, and Paolo Tarantino, MD, PhD, discuss approaches to maintenance and subsequent lines of therapy for patients with HER2+ advanced breast cancer, including those with CNS metastases.

My guest today is Dr. Robert Melillo. Dr. Melillo shares his 35-year journey from athletic injuries and chiropractic roots to developmental cognitive neuroscience and founder of the Melillo Method. Driven by his own children's challenges and a deep commitment to preserving their extraordinary gifts, he explains Autism as a treatable developmental imbalance rooted in brain immaturity—caused by retained primitive reflexes, disrupted right-left asymmetry, and poor transition from short-range to long-range connectivity. Emphasizing a bottom-up, root-cause approach over symptom management, he describes how remediating reflexes, stimulating right-brain activity, and balancing networks can unlock speech, motor control, and potential in non-speaking individuals—highlighting the human brain's unique evolutionary vulnerability and adaptability while offering hope for meaningful change without erasing unique brilliance.Dr. Melillo https://www.drrobertmelillo.comYT https://www.youtube.com/@themelillomethodInstagram https://www.instagram.com/drrobertmelillo/White Board Series: Serotonin's Role in Development for Sensory Maps (not mood) https://youtu.be/Pbovstb82i4White Board Series: Basal Ganglia (Go/No-GO), Neural Correlates, & "Motivation" https://www.youtube.com/watch?v=hTW8CSPVEGcWhite Board Series: Basal Ganglia No-Go area & Arkeypallidial Cells https://www.youtube.com/watch?v=XHZ_5HthUWsDaylight Computer Company, use "autism" for $50 off at https://buy.daylightcomputer.com/autismChroma Light Devices, use "autism" for 10% discount at https://getchroma.co/?ref=autismFig Tree Christian Golf Apparel & Accessories, use "autism" for 10% discount at https://figtreegolf.com/?ref=autism0:00 Dr. Robert Melillo5:24 The Nature of Gifts & Vulnerabilities with Autism15:26 The Evolution of the Human Brain & Bipedalism; CNS is to move the living organism; Left Brain, Right Brain25:20 Functional Connectivity & Movements; Left Brain-Right Brain36:46 The Immature Brain; Autism means "Self"38:54 Interventions for Maturing the Brain & Movements42:46 The Melillo Method & Upstream Individualized Interventions47:47 GI and the Nervous Systems; Excitation/Inhibition52:21 Melillo Method55:40 Giving a Voice to Non-Verbals; Sensory Map, Somatosensory & Homunculus1:03:00 The Basal Ganglia & Motor Movements1:06:34 Bridging Clinical & Neuroscience Research & MethodsX: https://x.com/rps47586YT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

Alprazolam is a short-acting benzodiazepine that enhances the inhibitory effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor. Clinically, this results in anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. After oral administration, alprazolam is rapidly absorbed, with onset of action typically within 30–60 minutes. It undergoes extensive hepatic metabolism primarily via CYP3A4 to inactive metabolites, and has an elimination half-life of approximately 11 hours, which may be prolonged in elderly patients or those with hepatic impairment. Common adverse effects include sedation, dizziness, impaired coordination, and cognitive slowing. More serious risks include respiratory depression, especially when combined with opioids, alcohol, or other CNS depressants. Clinically, alprazolam should be used at the lowest effective dose for the shortest possible duration. Abrupt discontinuation should be avoided; gradual tapering is essential to reduce withdrawal risk. It is a controlled substance that carries the risk of addiction and dependence. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101

In part one of this two-part series, Dr. Stacey Clardy talks with Drs. Ayush Gupta and Kuntal Sen about the phenotypes commonly seen in CNS inflammatory and demyelinating diseases, and discuss genetic conditions in patients who do not precisely meet classic diagnostic criteria. Read the related article in Neurology® Genetics.  Disclosures can be found at Neurology.org. 

Wes Youngberg, DrPH, MPH, CNS, FACLM, and Will Tuttle, Ph.D., provide evidence-based strategies to combat inflammation and protect memory and brain health. Learn practical nutrition and lifestyle techniques for optimal cognitive and overall wellness. #BrainHealth #AntiInflammatoryDiet #MemoryCare

Listen Online: About this episode: In this episode, The First Lady of Nutrition sits down with Dr. David Minkoff, author of The Search for the Perfect Protein, for a deep and eye-opening conversation about why protein may be one of the most misunderstood—and underestimated—nutrients in modern health. A former vegetarian and lifelong athlete, Dr. Minkoff shares what decades of clinical experience have taught him about amino acid deficiency, protein malnourishment, and why so many people struggle with fatigue, weight gain, weak bones, and poor recovery despite “eating enough.” Together, Ann Louise and Dr. Minkoff explore how the body actually uses protein, why absorption matters more than intake, and how gut health, stomach acid, and even acid-blocking medications can quietly interfere with rebuilding muscle, skin, bone, and nerve tissue. Dr. Minkoff explains his concept of “protein turnover”—the idea that your body is constantly rebuilding itself—and why amino acid sufficiency becomes more critical with age, especially for women concerned about bone density and balance. They also touch on the carnivore diet, leaky gut, pre-digested amino acids, and why protein isn't just for athletes—it's fundamental at every age and stage of life. It's a practical, science-based conversation that may change how you think about protein, healing, and what your body truly needs to repair and thrive.The post The Secrets of the Perfect Protein first appeared on Ann Louise Gittleman, PhD, CNS.

Episode 210: Heat Stroke BasicsWritten by Jacob Dunn, MS4, American University of the Caribbean. Edits and comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice. Definition:Heat stroke represents the most severe form of heat-related illness, characterized by a core body temperature exceeding 40°C (104°F) accompanied by central nervous system (CNS) dysfunction. Arreaza: Key element is the body temperature and altered mental status. Jacob: This life-threatening condition arises from the body's failure to dissipate heat effectively, often in the context of excessive environmental heat load or strenuous physical activity. Arreaza: You mentioned, it is a spectrum. What is the difference between heat exhaustion and heat stroke? Jacob: Unlike milder heat illnesses such as heat exhaustion, heat stroke involves multisystem organ dysfunction driven by direct thermal injury, systemic inflammation, and cytokine release. You can think of it as the body's thermostat breaking under extreme stress — leading to rapid, cascading failures if not addressed immediately. Arreaza: Tell us what you found out about the pathophysiology of heat stroke?Jacob: Pathophysiology: Under normal conditions, the body keeps its core temperature tightly controlled through sweating, vasodilation of skin blood vessels, and behavioral responses like seeking shade or drinking water. But in extreme heat or prolonged exertion, those mechanisms get overwhelmed.Once core temperature rises above about 40°C (104°F), the hypothalamus—the brain's thermostat—can't keep up. The body shifts from controlled thermoregulation to uncontrolled, passive heating. Heat stroke isn't just someone getting too hot—it's a full-blown failure of the body's heat-regulating system. Arreaza: So, it's interesting. the cell functions get affected at this point, several dangerous processes start happening at the same time.Jacob: Yes: Cellular Heat InjuryHigh temperatures disrupt proteins, enzymes, and cell membranes. Mitochondria start to fail, ATP production drops, and cells become leaky. This leads to direct tissue injury in vital organs like the brain, liver, kidneys, and heart.Arreaza: Yikes. Cytokines play a big role in the pathophysiology of heat stroke too. Jacob: Systemic Inflammatory ResponseHeat damages the gut barrier, allowing endotoxins to enter the bloodstream. This triggers a massive cytokine release—similar to sepsis. The result is widespread inflammation, endothelial injury, and microvascular collapse.Arreaza: What other systems are affected?Coagulation AbnormalitiesEndothelial damage activates the clotting cascade. Patients may develop a DIC-like picture: microthrombi forming in some areas while clotting factors get consumed in others. This contributes to organ dysfunction and bleeding.Circulatory CollapseAs the body shunts blood to the skin for cooling, perfusion to vital organs drops. Combine that with dehydration from sweating and fluid loss, and you get hypotension, decreased cardiac output, and worsening ischemia.Arreaza: And one of the key features is neurologic dysfunction.Jacob: Neurologic DysfunctionThe brain is extremely sensitive to heat. Encephalopathy, confusion, seizures, and coma occur because neurons malfunction at high temperatures. This is why altered mental status is the hallmark of true heat stroke.Arreaza: Cell injury, inflammation, coagulopathy, circulatory collapse and neurologic dysfunction. Jacob: Ultimately, heat stroke is a multisystem catastrophic event—a combination of thermal injury, inflammatory storm, coagulopathy, and circulatory collapse. Without rapid cooling and aggressive supportive care, these processes spiral into irreversible organ failure.Background and Types:Arreaza: Heat stroke is part of a spectrum of heat-related disorders—it is a true medical emergency. Mortality rate reaches 30%, even with optimal treatment. This mortality correlates directly with the duration of core hyperthermia. I'm reminded of the first time I heard about heat stroke in a baby who was left inside a car in the summer 2005. Jacob: There are two primary types: -nonexertional (classic) heat stroke, which develops insidiously over days and predominantly affects vulnerable populations like children, the elderly, and those with chronic illnesses during heat waves; -exertional heat stroke, which strikes rapidly in young, otherwise healthy individuals, often during intense exercise in hot, humid conditions. Arreaza: In our community, farm workers are especially at risk of heat stroke, but any person living in the Central Valley is basically at risk.Jacob: Risk factors amplify vulnerability across both types, including dehydration, cardiovascular disease, medications that impair sweating (e.g., anticholinergics), and acclimatization deficits. Notably, anhidrosis (lack of sweating) is common but not required for diagnosis. Hot, dry skin can signal the shift from heat exhaustion to stroke. Arreaza: What other conditions look like heat stroke?Differential Diagnosis:Jacob: Presenting with altered mental status and hyperthermia, heat stroke demands a broad differential to avoid missing mimics. -Environmental: heat exhaustion, syncope, or cramps. -Infectious etiologies like sepsis or meningitis must be ruled out. -Endocrine emergencies such as thyroid storm, pheochromocytoma, or diabetic ketoacidosis (DKA) can overlap. -Neurologic insults include cerebrovascular accident (CVA), hypothalamic lesions (bleeding or infarct), or status epilepticus. -Toxicologic culprits are plentiful—sympathomimetic or anticholinergic toxidromes, salicylate poisoning, serotonin syndrome, malignant hyperthermia, neuroleptic malignant syndrome (NMS), or even alcohol/benzodiazepine withdrawal. When it comes to differentials, it is always best to cast a wide net and think about what we could be missing if this is not heat stroke. Arreaza: Let's say we have a patient with hyperthermia and we have to assess him in the ER. What should we do to diagnose it?Jacob: Workup:Diagnosis is primarily clinical, hinging on documented hyperthermia (>40°C) plus CNS changes (e.g., confusion, delirium, seizures, coma) in a hot environment. Arreaza: No single lab confirms it, but targeted testing allows us to detect complications and rule out alternative diagnosis. Jacob: -Start with ECG to assess for dysrhythmias or ischemic changes (sinus tachycardia is classic; ST depressions or T-wave inversions may hint at myocardial strain). -Labs include complete blood count (CBC), comprehensive metabolic panel (electrolytes, renal function, liver enzymes), glucose, arterial blood gas, lactate (elevated in shock), coagulation studies (for disseminated intravascular coagulation, or DIC), creatine kinase (CK) and myoglobin (for rhabdomyolysis), and urinalysis. Toxicology screen if history suggests. Arreaza: I can imagine doing all this while trying to cool down the patient. What about imaging?-Imaging: chest X-ray for pulmonary issues, non-contrast head CT if neurologic concerns suggest edema or bleed (consider lumbar puncture if infection suspected). It is important to note that continuous core temperature monitoring—via rectal, esophageal, or bladder probe—is essential, not just peripheral skin checks. Arreaza: TreatmentManagement:Time is tissue here—initiate cooling en route, if possible, as delays skyrocket morbidity. ABCs first: secure airway (intubate if needed, favoring rocuronium over succinylcholine to avoid hyperkalemia risk), support breathing, and stabilize circulation. -Remove the patient from the heat source, strip clothing, and launch aggressive cooling to target 38-39°C (102-102°F) before halting to prevent rebound hypothermia. -For exertional cases, ice-water immersion reigns supreme—it's the fastest method, with immersion in cold water resulting in near-100% survival if started within 30 minutes. -Nonexertional benefits from evaporative cooling: mist with tepid water (15-25°C) plus fans for convective airflow. -Adjuncts include ice packs to neck, axillae, and groin; -room-temperature IV fluids (avoid cold initially to prevent shivering); -refractory cases, invasive options like peritoneal lavage, endovascular cooling catheters, or even ECMO. -Fluid resuscitation with lactated Ringer's or normal saline (250-500 mL boluses) protects kidneys and counters rhabdomyolysis—aim for urine output of 2-3 mL/kg/hour. Arreaza: What about medications?Jacob: Benzodiazepines (e.g., lorazepam) control agitation, seizures, or shivering; propofol or fentanyl if intubated. Avoid antipyretics like acetaminophen. For intubation, etomidate or ketamine as induction agents. Hypotension often resolves with cooling and fluids; if not, use dopamine or dobutamine over norepinephrine to avoid vasoconstriction. Jacob: What IV fluid is recommended/best for patients with heat stroke?Both lactated Ringer's solution and normal saline are recommended as initial IV fluids for rehydration, but balanced crystalloids such as LR are increasingly favored due to their lower risk of hyperchloremic metabolic acidosis and AKI. However, direct evidence comparing the two specifically in the setting of heat stroke is limited. Arreaza: Are cold IV fluids better/preferred over room temperature fluids?Cold IV fluids are recommended as an adjunctive therapy to help lower core temperature in heat stroke, but they should not delay or replace primary cooling methods such as cold-water immersion. Cold IV fluids can decrease core temperature more rapidly than room temperature fluids. For example, 30mL/kg bolus of chilled isotonic fluids at 4 degrees Celsius over 30 minutes can decrease core temperature by about 1 degree Celsius, compared to 0.5 degree Celsius with room temperature fluids. Arreaza: Getting cold IV sounds uncomfortable but necessary for those patients. Our favorite topic.Screening and Prevention:-Heat stroke prevention focuses on public health and individual awareness rather than routine testing. -High-risk groups—elderly, children, athletes, laborers, or those on impairing meds—should acclimatize gradually (7-14 days), hydrate preemptively (electrolyte solutions over plain water), and monitor temperature in exertional settings. -Communities during heat waves need cooling centers and alerts. -For clinicians, educate patients with CVD or obesity about early signs like dizziness or nausea. -No formal "screening" exists, but vigilance in EDs during summer surges saves lives. -Arreaza: I think awareness is a key element in prevention, so education of the public through traditional media like TV, and even social media can contribute to the prevention of this catastrophic condition.Jacob: Ya so heat stroke is something that should be on every physician's radar in the central valley especially in the summer time given the hot temperatures. Rapid recognition is key. Arreaza: Thanks, Jacob for this topic, and until next time, this is Dr. Arreaza, signing off.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! References:Gaudio FG, Grissom CK. Cooling Methods in Heat Stroke. J Emerg Med. 2016 Apr;50(4):607-16. doi: 10.1016/j.jemermed.2015.09.014. Epub 2015 Oct 31. PMID: 26525947. https://pubmed.ncbi.nlm.nih.gov/26525947/.Platt, M. A., & LoVecchio, F. (n.d.). Nonexertional classic heat stroke in adults. In UpToDate. Retrieved September 7, 2025, from https://www.uptodate.com/contents/nonexertional-classic-heat-stroke-in-adults. (Key addition: Emphasizes insidious onset in at-risk populations and the role of urban heat islands in exacerbating classic cases.) Heat Stroke. WikEM. Retrieved December 3, 2025, from https://wikem.org/wiki/Heat_stroke. (Key additions: Details on cooling rates for immersion therapy, confirmation that anhidrosis is not diagnostic, and fluid titration to urine output for rhabdomyolysis prevention.)Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. 

Title: Wellness Podcast: Healing Ourselves - Neurosurgeons as Whole Person Health Advocates Guest: Ann Stroink Hosts: Brian Gantwerker and Lara Massie In this episode of the CNS wellness podcast, we speak to a career neurosurgeon who has transitioned into a new role as a whole person health advocate and practitioner. Dr. Ann Stroink enlightens us with a unique and fresh perspective that's important both for us as Physicians and as people ourselves. We get front row seat in making tangible changes that can help our patients in their recovery from surgery and simultaneously positively affect our own health.  We hope you join us in the conversation.  

We love to hear from our listeners. Send us a message.In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA). Dr. Putzki walks us through the six-year development journey behind the STEER and STRENGTH Phase 3 programs. And we explore what the expanded age-range label means for patients who were previously left behind, why intrathecal, fixed-dose AAV delivery represents a pivotal advance for safety, efficacy, and scalability. He details how the Itvisma program is informing Novartis' broader gene therapy strategy across neuromuscular and CNS diseases, and more.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Your off-season choices today determine your race day results tomorrow.Most runners get the transition season completely wrong—they either hammer through on their way to burnout or disappear entirely and spend January rebuilding from scratch. In this episode, we break down what actually works for year-over-year improvement.We cover why taking zero time off after race season is a recipe for injury and plateau, the science of post-race recovery (CNS fatigue, hormonal reset, glycogen restoration), and why detraining fears are almost always overblown. We play Hot or Not with common off-season approaches so you know what to keep and what to ditch, discuss frequency goals vs. volume goals and why the switch changes everything, and talk about building accountability systems that don't rely on motivation.The bottom line: rest is part of training—make this a core belief in 2026. You can cut volume in half for 4-6 weeks and only lose 5-10% fitness. Simpler plans are more likely to be followed. And your January determines your July.Before spring hits, take 2-4 weeks of intentional rest after your last A-race, complete a full season assessment to identify 2-3 specific pain points, set frequency goals for transition season, build at least one accountability system into your training, and schedule monthly low-key events to stay engaged.Connect with us:Email: microcosm.coaching@gmail.comWebsite: microcosm-coaching.com

Drs. Yu and Herzberg discuss recent developments in HER2- and EGFR-targeted therapies for lung cancer, focusing on clinical trial results at ESMO 2025. Key highlights include promising response rates, toxicity profiles, and the potential for these targeted therapies to treat patients with specific genetic mutations, particularly those with CNS metastases.

This week we're coming off a solid crew Christmas party with the Keto Savage crew—good food, good company, and a surprisingly competitive keto dessert showdown. We talk through some of the highlights, including a few creative “brick-based” desserts, cast-iron chaos baking, and why consistency always beats perfection, even when you're experimenting in the kitchen.We also get into holiday logistics around the office—skeleton crew operations, shipping timelines, inventory drops, and how we're handling fulfillment with people traveling. If you're placing orders this week, everything will go out as soon as we're back in the normal workflow, so appreciate everyone's patience around the holidays.On the training side, we break down how things are progressing right now—strength is climbing, bodyweight is stable, and offseason macros are doing their job. We talk deloads, CNS fatigue, training while traveling, and why listening to objective performance markers matters more than just “feeling tired.” There's also some discussion around trail running, endurance work, and getting prepped for upcoming challenges like the mud run.Nutrition-wise, we dig into fasting protocols, including multi-day fasts, water vs. dry fasting, and why neither of us uses fasting as a fat-loss tool. For us, it's about cognitive reset, gut health, and long-term sustainability—never starvation. We also talk through how higher intake, consistent training, and repeatable food choices remove decision fatigue and make progress inevitable.We wrap things up with a broader mindset conversation heading into the new year—why we don't really believe in “resolutions,” why progress is the most motivating force there is, and how committing to small daily actions compounds over time. Whether it's training, nutrition, business, or relationships, you're either moving forward or falling behind—so focus on something you can execute every single day and build from there.Merry Christmas, happy holidays, and we'll see you heading into World Carnivore Month and the start of another strong year.Greg Mahler is also a lifetime natural bodybuilder, and can be followed on Instagramhttps://www.instagram.com/ketogreg80/Register For My FREE Masterclass: https://www.ketobodybuilding.com/registration-2Get Keto Brick: https://www.ketobrick.com/Subscribe to the podcast: https://open.spotify.com/show/42cjJssghqD01bdWBxRYEg?si=1XYKmPXmR4eKw2O9gGCEuQ

Listen Online: About this episode: The First Lady of Nutrition welcomes Tamera Campbell, a dear friend and revered acquaintance. Tamera is the founder of E3LIVE, and the conversation begins in a remote mountain lake in southern Oregon—one of the only places in the world where a rare, nutrient-dense blue-green algae can be harvested sustainably. In this episode, Tamera shares the story behind E3LIVE and explains what makes its signature ingredient, Aphanizomenon flos-aquae (AFA), so special—from its exceptional purity and rigorous testing to its unique ability to support brain function, mental clarity, immune health, digestion, and cellular nourishment. Ann Louise and Tamera also explore why professional and recreational athletes have gravitated toward AFA for its natural anti-inflammatory properties, recovery support, and sustained energy. They break down the science behind blue-green algae's rare blue pigment—sometimes called the “molecule of love” for how it interacts with the brain—and explain why it's gentle enough for children and infants, yet effective for those with high physical demands.   Learn more about E3Live at https://e3live.com/?bg_ref=rZg8FMANhuThe post The Extraordinary Power of Blue-Green Algae first appeared on Ann Louise Gittleman, PhD, CNS.

Kendall Mackintosh, MS, CNS, LDN, INHC is a clinically trained nutrition expert who blends evidence-based science with integrative health coaching to address root causes—not just symptoms. With a focus on metabolic health and sustainable lifestyle change, Kendall helps clients turn complex nutrition science into practical, life-changing results. In this episode, Dr. Tro, Dr. Brian, and Kendall talk about… (00:00) Intro (02:19) How Kendall became involved in the MAHA movement (15:45) Medical misinformation and getting de platformed (18:22) The low-hanging fruit you can take advantage of to help protect your family's health (23:26) Glyphosates, heavy metals, micro plastics, mold, and parasites (32:36) Testing for mold, heavy metals, and other toxins (34:29) Parasite tests (39:11) Fasting and gut health (43:57) The vaccine religion (50:16) Moms Across America (58:25) Outro For more information, please see the links below. Thank you for listening! Links: Please consider supporting us on Patreon: https://www.lowcarbmd.com/ Kendall Mackintosh: Website: https://kendallmackintosh.com IG: https://www.instagram.com/kendall.mackintosh/ X: https://x.com/healthy_kendall Dr. Brian Lenzkes:  Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author Dr. Tro Kalayjian:  Website: https://www.doctortro.com/ Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/ Toward Health App Join a growing community of individuals who are improving their metabolic health; together.  Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more.  Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888  Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://doctortro.com/community/ 

In this live Red Delta Project Q&A, Matt digs into a big 2025 lesson that came out of writing Beautiful Strength: diet and exercise can absolutely influence how you look, feel, and perform—but if you chase a goal blindly, your habits can backfire and give you the opposite result. Using a “hit the target” analogy (and a few colorful side stories), he explains why your results come from achieving the right objective, not from grinding harder, eating “cleaner,” or following a program with blind loyalty.From there, the episode turns into a rapid-fire Q&A on practical training topics: whether you need to go to failure with Double Tap Training, how to balance intensity with reps and rest, walking as conditioning, yoga vs direct flexibility work, knee stability, building arms with compounds, grip changes, circuit training for endurance, and more. There's also a surprisingly thoughtful section on accepting hair loss—framed through confidence, control, and reframing the story you tell yourself.

Moxifloxacin is a fourth-generation fluoroquinolone that works by inhibiting bacterial DNA gyrase and topoisomerase IV—two enzymes essential for DNA replication, repair, and transcription. By blocking both targets, it provides broad-spectrum activity against gram-positive, gram-negative, and atypical pathogens. Its enhanced gram-positive coverage, especially against Streptococcus pneumoniae, distinguishes it from earlier fluoroquinolones like ciprofloxacin. Pharmacokinetically, moxifloxacin has excellent oral bioavailability, meaning the PO and IV doses are essentially interchangeable. It distributes well into tissues like the lungs and sinuses, making it a frequent choice for respiratory infections. With a long half-life of about 12 hours, once-daily dosing is standard. Adverse effects are similar to the fluoroquinolone class, with concerns including tendonitis and tendon rupture, QT interval prolongation, CNS effects like confusion or agitation—particularly in older adults—and the risk of peripheral neuropathy. Moxifloxacin is especially notable for a higher propensity toward QT prolongation compared with some of its peers, making it important to avoid in patients with existing QT issues or those taking other QT-prolonging medications. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101

She grew up with no roadmap, no support, and no clear path forward. One pull-up changed everything, leading her into the Army and a career in explosive ordnance disposal. Twelve years later, Kaitlyn Hernandez built a life defined by discipline, resilience, and service. She shares how daily discomfort, purpose, and small hard choices shaped her mindset, helping her run a bomb-suit mile, set a world record, and tackle some of the military's toughest challenges.   3 Key Learnings: Small daily challenges build discipline, mental toughness, and high-stakes performance Leaning into discomfort strengthens resilience, focus, and decision-making Purpose, service, and consistent action create long-term endurance and growth   3 Tools / Frameworks: Controlled discomfort protocols: rucking, cold exposure, physical stress CNS reset through structured challenges Mindset reframing: "I get to, not I have to" and "Fix your face" to shift state   Timestamps: 00:51 – Growing up without structure and finding purpose in service 02:27 – Joining the military and discovering direction 04:08 – How she chose the bomb squad and what EOD means 07:48 – What EOD teams do during stateside and presidential missions 09:14 – How bomb suit training works and what "bomb suit dumb" means 10:28 – Breaking the world record and the strategy behind it 12:59 – Running a bomb-suit mile on all seven continents 13:39 – Preparing for the Antarctica mission and raising awareness 18:50 – Her step-by-step advice for building resilience through daily discomfort   Start with one hard thing, lean into discomfort, and build discipline through daily action.